Familial Cold Autoinflammatory Syndrome
📧 Sign up to get email alerts when something new happens for Familial Cold Autoinflammatory Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Pathogenesis of Physical Induced Urticarial Syndromes
Completed clinical trial investigating the pathogenesis of physical induced urticarial syndromes, including immediate hypersensitivity and a…
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) [Phase 2]
Phase 2 study of DFV890 assessing safety, tolerability and efficacy in Familial Cold Autoinflammatory Syndrome completed; results posted May…
-
FDA label_change · 2021-03-18FDA Approved: ARCALYST — Supplemental Application (Kiniksa Pharmaceuticals (UK), Ltd.)
The FDA approved a supplemental application for ARCALYST (rilonacept) by Kiniksa Pharmaceuticals (UK), updating the drug's labeling to refle…
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase [Phase 3]
Phase 3 study assessing 6-month efficacy and safety of canakinumab in Japanese patients with cryopyrin-associated periodic syndromes, includ…
-
CLINICAL_TRIALS withdrawal · 2017-07-02Clinical Trial Update: A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease [Phase 1, Phase 2]
A phase 1/2 study of XOMA 052 in familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and Behçet's disease has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-09-23FDA Approved: ILARIS — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for ILARIS (canakinumab) submitted by Novartis Pharmaceuticals Corporation, resulting in an upda…
-
CLINICAL_TRIALS trial_result · 2016-08-03Clinical Trial Update: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 trial assessing efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric patients with cryopyrin-associated periodic s…
-
CLINICAL_TRIALS trial_result · 2016-03-28Clinical Trial Update: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
This registry study assesses clinical outcomes and safety of canakinumab (Ilaris) in patients with cryopyrin-associated periodic syndromes (…
-
CLINICAL_TRIALS trial_result · 2015-08-18Clinical Trial Update: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 trial evaluating ACZ885 (canakinumab) for efficacy, safety and tolerability in pediatric patients with Cryopyrin-associated periodic…
-
CLINICAL_TRIALS trial_result · 2011-05-27Clinical Trial Update: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 study evaluating ACZ885 (canakinumab) for efficacy and safety in cryopyrin-associated periodic syndromes, including familial cold au…
-
CLINICAL_TRIALS trial_result · 2009-11-13Clinical Trial Update: Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) [Phase 3]
Phase 3 trial of rilonacept for Cryopyrin-associated periodic syndromes (CAPS) completed with results posted in 2009.
-
FDA approval · 2009-06-17FDA Approved: ILARIS — Original Application (Novartis Pharmaceuticals Corporation)
The FDA approved ILARIS (canakinumab) under the original application for treatment of cryopyrin-associated periodic syndromes, including fam…
-
CLINICAL_TRIALS trial_result · 2009-02-17Clinical Trial Update: Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms [Phase 2]
Phase 2 trial update evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of ACZ885 (canakinumab) in patients with NLRP3 mutat…
-
FDA approval · 2008-02-27FDA Approved: ARCALYST — Original Application (Kiniksa Pharmaceuticals (UK), Ltd.)
FDA approved ARCALYST (rilonacept) from its original Biologics License Application for the treatment of cryopyrin-associated periodic syndro…